Lifeboat Foundation

This Week in Science: The First Privately Backed Moon Mission, Using Gene Therapy to Reverse Aging, Artificial Veins and Arteries, and More.

Go here for a clickable image: http://futurism.com/images/this-week-in-science-october-4th-11th-2015/?src=home

Sources
Detecting All Viruses:http://futurism.com/5srzA
Water on Pluto: http://futurism.com/aO2av
Kidney Tissue from Stem Cells: http://futurism.com/DLDON
Converting Algae Blooms into Electrodes: http://futurism.com/w9ez
Fixing Holes in Heart: http://futurism.com/a13Jd
Reversing Aging: http://futurism.com/TjaTL
Private Moon Mission: http://futurism.com/9V626
Artificial Veins: http://futurism.com/rKNzH

Read more

Scientists using data from NASA’s Kepler mission have confirmed the first near-Earth-size planet orbiting in the habitable zone of a sun-like star. The habitable zone is the region around a star where temperatures are just right for water to exist in its liquid form.

The artistic concept compares Earth (left) to the new planet, called Kepler-452b, which is about 60 percent larger. The illustration represents one possible appearance for Kepler-452b — scientists do not know whether the planet has oceans and continents like Earth.

Both planets orbit a G2-type star of about the same temperature; however, the star hosting Kepler-452b is 6 billion years old, 1.5 billion years older than our sun. As stars age, they become larger, hotter and brighter, as represented in the illustration. Kepler-452b’s star appears a bit larger and brighter.

Continue reading “Close cousins? Comparison between Earth and Kepler-452b and their host stars” »

Liz Parrish is the Founder and CEO of BioViva Sciences USA Inc. BioViva is committed to extending healthy lifespans using gene therapy. Liz is known as “the woman who wants to genetically engineer you,” she is a humanitarian, entrepreneur and innovator and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of gene therapy, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and sits on the board of the International Longevity Alliance (ILA). She is an affiliated member of the Complex Biological Systems Alliance (CBSA) whose mission is to further scientific understanding of biological complexity and the nature and origins of human disease. She is the founder of BioTrove Investments LLC and the BioTrove Podcasts which is committed to offering a meaningful way for people to learn about and fund research in regenerative medicine. She is also the Secretary of the American Longevity Alliance (ALA) a 501©(3) nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular & regenerative medicine with the aim to get governments to consider aging a disease. I am not a medical doctor or scientist. I can not answer details of therapy. I would like to discuss my experience of creating BioViva, organizing the gene therapies, and then finally being able to administer it to the first human.

Read more

A 10 year study on yeast at the Buck Institute has uncovered 238 genes that when removed, are linked to longevity.

Read more

Mark Pollock became blind asa young man, and was paralyzed by an accident later. Now, he is taking steps with the help of a robotic exoskeleton.

Read more

“Vicarious, the mysterious company that’s been funded by Tesla and SpaceX CEO Elon Musk, Facebook’s Mark Zuckerberg, and actor Ashton Kutcher, wants to do something completely radical — build the world’s first human-level artificial intelligence (AI).”

Smarter than Siri and Cortana.

Read more

Seventeen years ago, Helen Greiner was scrambling to find investors to back her company’s development of a robot that would clean people’s houses. As she made the rounds of venture capitalists, the responses ranged from “You’re not an Internet company” to “You’re too early stage” to “I would do this, but my partners would kill me.”

But Greiner and her partners, Colin Angle and MIT robotics professor Rodney Brooks, persevered, funneling money from their firm’s contract engineering work to fund the robot project. Today, that company, iRobot Corp. of Bedford, is one of the nation’s largest makers of home robots, generating more than $500 million in annual sales from its Roomba floor vacuum and other products, and employing 600 people, including 500 in Massachusetts.

iRobot is an anchor of a burgeoning Massachusetts robotics industry that includes more than 100 companies, employs more than 3,000, and attracts tens, if not hundreds, of millions of dollars of investments. Since 2008, at least 20 robotics startups have launched in Massachusetts. Venture capital funding of the local industry tripled to more than $60 million in 2012, the most recent year available, from less than $20 million in 2008, according to the Massachusetts Technology Leadership Council, a trade group in Burlington.

Read more

BOSTON, Sept. 29, 2015 /PRNewswire/ — Veritas Genetics today announced that the company is making it possible for participants in the Personal Genome Project (PGP) to be among the first to get their whole genome sequenced and interpreted for less than a $1,000.

Led by Veritas Genetics Co-Founder Dr. George Church, Professor of Genetics at Harvard Medical School and Director of the Personal Genome Project, PGP is a long-term effort to sequence thousands of complete genomes to enable research into personal genomics and personalized medicine. PGP has more than 16,000 participants worldwide.

The “$1,000 Genome” has long been considered the tipping point when sequencing and interpreting the human genome becomes commonplace and begins to rapidly increase what is known and to dramatically impact healthcare. The catchphrase underscores how far science has come since the actual cost of the Human Genome Project, estimated at $2.7 billion spent over a decade.

Read more

https://youtube.com/watch?v=xU8kDSTzYd4

This short video (with some fun integrated graphics) is from an interview I did with El País (the largest newspaper in Spain). It highlights some of the emerging technologies and approaches which have the potential to shift health, medicine and biopharma from an intermittent and reactive physician-centric mode, to an era of more continuous data and a proactive approach in which the individual is increasingly empowered and integrated into personalized wellness, diagnosis and therapy.

Read more